Clinical trial · no report yet · Phase 3
SURVIVE HERoes
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
- NCT06643585 ↗
- Recruiting
- Prof. Wolfgang Janni
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- SURVIVE HERoes - A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab-Deruxtecan; Physicians Choice (PhC).
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 180 (estimated)
- Primary outcomes
- ctDNA clearance rate 12 months after randomization
- Sponsor
- Prof. Wolfgang Janni
- Start
- Apr 22, 2025
- Primary completion
- Apr 22, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT06643585 · updated May 2, 2025